Core Viewpoint - A significant boardroom shake-up at Novo Nordisk has granted unprecedented power to its primary shareholder, the Novo Nordisk Foundation, causing concern among investors despite demands for stronger leadership at the company known for its weight-loss treatment Wegovy [1] Group 1 - The Novo Nordisk Foundation has gained unprecedented influence over the company's operations following the recent board changes [1] - Investors are expressing unease regarding the implications of this shift in power within the company [1] - There are ongoing calls for enhanced leadership at Novo Nordisk, particularly in light of its role in the weight-loss treatment market [1]